27851729|t|In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
27851729|a|Targeted genome editing via engineered nucleases is an exciting area of biomedical research and holds potential for clinical applications. Despite rapid advances in the field, in vivo targeted transgene integration is still infeasible because current tools are inefficient, especially for non-dividing cells, which compose most adult tissues. This poses a barrier for uncovering fundamental biological principles and developing treatments for a broad range of genetic disorders. Based on clustered regularly interspaced short palindromic repeat/Cas9 (CRISPR/Cas9) technology, here we devise a homology-independent targeted integration (HITI) strategy, which allows for robust DNA knock-in in both dividing and non-dividing cells in vitro and, more importantly, in vivo (for example, in neurons of postnatal mammals). As a proof of concept of its therapeutic potential, we demonstrate the efficacy of HITI in improving visual function using a rat model of the retinal degeneration condition retinitis pigmentosa. The HITI method presented here establishes new avenues for basic research and targeted gene therapies.
27851729	0	7	In vivo	T082	C1515655
27851729	8	22	genome editing	T063	C4279981
27851729	27	38	CRISPR/Cas9	T063	C1513384
27851729	48	89	homology-independent targeted integration	T063	C1513384
27851729	99	113	genome editing	T063	C4279981
27851729	118	128	engineered	T063	C0017387
27851729	129	138	nucleases	T116,T126	C0597094
27851729	162	181	biomedical research	T062	C0005540
27851729	206	227	clinical applications	T201	C0683325
27851729	266	273	in vivo	T082	C1515655
27851729	274	304	targeted transgene integration	T045	C1158478
27851729	341	346	tools	T063	C4279981
27851729	379	397	non-dividing cells	T025	C1512899
27851729	424	431	tissues	T024	C0040300
27851729	481	502	biological principles	T080	C0205460
27851729	518	528	treatments	T061	C0087111
27851729	550	567	genetic disorders	T047	C0019247
27851729	578	664	clustered regularly interspaced short palindromic repeat/Cas9 (CRISPR/Cas9) technology	T063	C1513384
27851729	683	740	homology-independent targeted integration (HITI) strategy	T063	C1513384
27851729	766	769	DNA	T114,T123	C0012854
27851729	770	778	knock-in	T062	C1517676
27851729	787	795	dividing	T025	C0230517
27851729	800	818	non-dividing cells	T025	C1512899
27851729	819	827	in vitro	T059,T062	C3850137
27851729	851	858	in vivo	T082	C1515655
27851729	876	883	neurons	T025	C0027882
27851729	887	896	postnatal	T079	C0443281
27851729	897	904	mammals	T015	C0024660
27851729	936	947	therapeutic	T169	C0302350
27851729	948	957	potential	T080	C3245505
27851729	990	994	HITI	T063	C1513384
27851729	1008	1023	visual function	T040	C0042789
27851729	1032	1041	rat model	T008	C0599779
27851729	1049	1069	retinal degeneration	T046	C0035304
27851729	1080	1100	retinitis pigmentosa	T047	C0035334
27851729	1106	1117	HITI method	T063	C1513384
27851729	1161	1175	basic research	T062	C0681833
27851729	1180	1188	targeted	T169	C1521840
27851729	1189	1203	gene therapies	T061	C0017296